World Health Organization Grants Name ‘Lanifibranor’ to Inventiva’s IVA337 to Treat SSc, NASH
Inventiva Pharma, which develops therapies for fibrotic diseases, said the World Health Organization (WHO) has granted the International Non-Proprietary Name lanifibranor for IVA337. Lanifibranor is Inventiva’s lead drug candidate now being investigated to treat systemic sclerosis (SSc) and non-alcoholic steatohepatitis (NASH). The anti-fibrotic drug functions by activating three isoforms of…